medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (6)


Improvement in Waldenström’s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals

Crespi M, Demarzo MG, Brunacci M, Pellegatta G, Ferrando F, Ballestrero A, Grillo F, Savarino V, Giannini EG

Idioma: Ingles.
Referencias bibliográficas: 23
Paginas: 1072-1077
Archivo PDF: 480.94 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 2017; 14: 122-32.

  2. 2.Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017; 2: 427-34.

  3. 3.European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 325-36.

  4. 4.Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65: 524-31.

  5. 5.Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65: 804-12.

  6. 6.Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017; 45: 160-8.

  7. 7.Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol 2012; 2012: 638185.

  8. 8.Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016; 128: 2527-32.

  9. 8.Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-32.

  10. 9.Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 2016; 22: 8447-58.

  11. 10.Giordano TP, Henderon L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2017; 297: 2010-17.

  12. 11.de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-8.

  13. 12.Nipp R, Mitchell A, Pishko A, Metjian A. Waldenström Macroglobulinemia in hepatitis C: case report and review of the current literature. Case Rep Oncol Med 2014; 2014: 165670.

  14. 13.Mihaila RG. Hepatitis C virus - associated B cell non-Hodgkin’s lymphoma. World J Gastroenterol 2016; 22: 6214-23.

  15. 14.Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a metaanalysis. J Viral Hep 2016; 23: 536-44.

  16. 15.Slager SL, Benavente Y, Blair A, Vermeulen R, Cerhan JR, Costantini AS, Monnereau A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 2014: 41-51.

  17. 16.Leleu X, O’Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, et al. Hepatitis C viral infection is not associated with Waldenström’s macroglobulinemia. Am J Hematol 2007; 82: 83-4.

  18. 17.Senín A, Broquetas T, Cañete N, Lens S, Londoño MC, Ferraro M, Forns X, et al. Aplastic anemia and severe myelosuppression with boceprevir or simeprevir-containing hepatitis C virus treatment. Ann Hepatol 2017; 16: 312-17.

  19. 18.Álvarez-Ruiz SB, García-Río I, Aragüés M, Fraga J, Locertales Pueyo J, Fernández-Herrera J, García-Díez A. Leucocytoclastic vasculitis, hepatitis C virus-associated mixed cryoglobulinaemia with biclonal gammopathy and Waldenström macroglobulinaemia. Br J Dermatol 2004; 151: 937-9.

  20. 19.Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood 2016; 128: 1321-8.

  21. 20.Giannini EG, Peck-Radosavljevic M. Platelet dysfunction: status of thrombopoietin in thrombocytopenia associated with chronic liver failure. Semin Thromb Hemost 2015; 41: 455-61.

  22. 21.Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-8.

  23. 22.Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE 2017; 12: e0185728.




2020     |     www.medigraphic.com